Article · 23 Jan 2026
ArticlePublished 21 Jul 2026
Endocrine sequencing in ESR1-mutant HR+/HER2â?? metastatic breast cancer: a two-case series
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Breast cancer is the most common cancer and the leading cause of cancer-related death in women worldwide, with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) tumors comprising approximately 70% of breast cancer. Endocrine therapy combined with cyclin dependent kinase 4 and 6 (CDK4/6) inhibitors is standard for advanced disease; however, resistance often develops, frequently driven by estrogen receptor 1 (ESR1) mutations. Emerging therapies, such as the oral selective estrogen receptor degraders (SERDs) Elacestrant, demonstrate significant benefit, particularly in ESR1-mutated tumors. We report two HR+/HER2− metastatic cases illustrating endocrine resistance and the evolving role of SERDs in management. Case presentations: Case 1 involved a premenopausal, breast cancer gene (BRCA) wild-type woman diagnosed in 2013 with estrogen receptor–positive (ER+)/progesterone receptor positive (PR+)/HER2-negative/invasive lobular carcinoma (ILC) of the left breast, who developed bone metastases three years after initial therapy; sequential endocrine therapy with Palbociclib and Denosumab maintained disease control, and Elacestrant was initiated in 2023 to overcome emerging ESR1 mutations (Y537N, Y537S), achieving 11 months of progression free survival (PFS) until temporary interruption for spinal surgery; subsequent progression required Capecitabine and palliative radiotherapy. Case 2 involved a 46-year-old woman diagnosed in 2020 with de novo bilateral breast cancer harboring ESR1 (Y537S, D538G), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) E545K, and GATA binding protein 3 (GATA3) S427fs mutations. She was started on Goserelin, Ribociclib (CDK4/6 inhibitor), Letrozole (aromatase inhibitor), and Denosumab. Disease progression in the bone was observed in May 2024, prompting a switch to Elacestrant in June 2024. This resulted in disease control for 15 months. Subsequent progression in October 2025 was managed with Capivasertib plus Fulvestrant. Conclusion: Carefully selected endocrine therapies can provide meaningful disease control in metastatic hormone receptor positive breast cancer, even in the presence of resistance associated mutations. Real-world evidence demonstrates that Elacestrant is effective in ER-positive, HER2-negative, ESR1 mutant disease, particularly when used earlier in the metastatic course. These findings highlight the clinical value of Elacestrant and underscore that the therapeutic potential of endocrine therapy should not be underestimated, with genomic profiling and prior treatment history guiding optimal sequencing.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Oncology & Cancer Case Reports.
Article · 15 Oct 2025
High-Grade Pulmonary Fetal Adenocarcinoma: A Case Report
Article · 29 Sep 2025
The future of chemotherapy nanotechnology ai and precision medicine
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalOncology & Cancer Case Reports
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Dina Hamza”
- BylineArticles whose byline prints “Mohammad Hourani”
- BylineArticles whose byline prints “Rawan Bdair”